Publication:
Proteomic and Metabolic Signatures of Esophageal Squamous Cell Carcinoma

dc.contributor.authorARĞA, KAZIM YALÇIN
dc.contributor.authorsKaragoz, Kubra; Lehman, Heather L.; Stairs, Douglas B.; Sinha, Raghu; Arga, Kazim Y.
dc.date.accessioned2022-03-12T20:28:38Z
dc.date.accessioned2026-01-11T16:31:26Z
dc.date.available2022-03-12T20:28:38Z
dc.date.issued2016
dc.description.abstractEsophageal squamous cell carcinoma (ESCC), which is the most common subtype of esophageal cancers, is the sixth leading cause of cancer deaths worldwide with a five-year survival rate of 19%. Identification of efficient biomarkers for early detection and better understanding of the molecular mechanisms of ESCC may offer reduced mortality. However, proper biomarkers for clinical diagnosis and prognosis have not been defined yet. In the presented study, we employed a systematic and integrative 'omics' strategy to reconstruct networks of transcriptional regulation and protein-protein interaction to identify novel biomarkers, potential molecular targets, and mechanisms of transcriptional control in ESCC. Towards this end, we revealed 30 down-regulated and 21 upregulated genes as ESCC specific biomarkers since these were differentially expressed between 91 ESCC tumor samples compared to normal tissues in five different datasets. We report the association of ACPP, C2orf54, DYNLT3, ENDOU, FMO2, and KANK1 (down-regulated genes) and COL10A1, FNDC3B, HOMER3, MARCKSL1, and RFC4 (up-regulated genes) to ESCC for the first time. Further, the ESCC driven molecular pathways were also constructed to elucidate the molecular mechanism of the disease; specifically several metabolic pathways were down-regulated while the signaling pathways were up-regulated. Additionally, reporter metabolites for ESCC were analyzed and metabolic dysfunction was ascertained in arachidonic acid metabolism and steroid hormone biosynthesis pathways. The multi-omics network strategy presented here may enable discovery of novel biomarkers and targets for personalized medicine in ESCC patients.
dc.identifier.doi10.2174/1568009616666160203113721
dc.identifier.eissn1873-5576
dc.identifier.issn1568-0096
dc.identifier.pubmed26845434
dc.identifier.urihttps://hdl.handle.net/11424/233949
dc.identifier.wosWOS:000387003900008
dc.language.isoeng
dc.publisherBENTHAM SCIENCE PUBL LTD
dc.relation.ispartofCURRENT CANCER DRUG TARGETS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSystems biology
dc.subjectbiomedicine
dc.subjectfunctional genomics
dc.subjectesophageal squamous cell carcinoma
dc.subjectbiomarker
dc.subjectTUMOR-SUPPRESSOR GENE
dc.subjectARACHIDONIC-ACID METABOLISM
dc.subjectLYMPH-NODE METASTASIS
dc.subjectGENOME-WIDE ANALYSIS
dc.subjectBREAST-CANCER
dc.subjectEXPRESSION PROFILES
dc.subjectTRANSCRIPTIONAL REGULATION
dc.subjectPROTEIN EXPRESSION
dc.subjectMESSENGER-RNA
dc.subjectIDENTIFICATION
dc.titleProteomic and Metabolic Signatures of Esophageal Squamous Cell Carcinoma
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage736
oaire.citation.issue8
oaire.citation.startPage721
oaire.citation.titleCURRENT CANCER DRUG TARGETS
oaire.citation.volume16

Files